International journal of radiation oncology, biology, physics 2018-03-01
A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer.
Abstract
Purpose
Two modern methods of reirradiation, intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), are established for patients with recurrent or second primary squamous cell carcinoma of the head and neck (rSCCHN). We performed a retrospective multi-institutional analysis to compare methods.
Methods and materials
Data from patients with unresectable rSCCHN previously irradiated to ≥40 Gy who underwent reirradiation with IMRT or SBRT were collected from 8 institutions. First, the prognostic value of our IMRT-based recursive partitioning analysis (RPA) separating those patients with unresectable tumors with an intertreatment interval >2 years or those with ≤2 years and without feeding tube or tracheostomy dependence (class II) from other patients with unresected tumors (class III) was investigated among SBRT patients. Overall survival (OS) and locoregional failure were then compared between IMRT and SBRT by use of 2 methods to control for baseline differences: Cox regression weighted by the inverse probability of treatment and subset analysis by RPA classification.
Results
The study included 414 patients with unresectable rSCCHN: 217 with IMRT and 197 with SBRT. The unadjusted 2-year OS rate was 35.4% for IMRT and 16.3% for SBRT (P<.01). Among SBRT patients, RPA classification retained an independent association with OS. On Cox regression weighted by the inverse probability of treatment, no significant differences in OS or locoregional failure between IMRT and SBRT were demonstrated. Analysis by RPA class showed similar OS between IMRT and SBRT for class III patients. In all class II patients, IMRT was associated with improved OS (P<.001). Further subset analysis demonstrated comparable OS when ≥35 Gy was delivered with SBRT to small tumor volumes. Acute grade ≥4 toxicity was greater in the IMRT group than in the SBRT group (5.1% vs 0.5%, P<.01), with no significant difference in late toxicity.
Conclusions
Reirradiation both with SBRT and with IMRT appear relatively safe with favorable toxicity compared with historical studies. Outcomes vary by RPA class, which informs clinical trial design. Survival is poor in class III patients, and alternative strategies are needed.
Related Questions
Do you give Cetuximab concurrently with SBRT for recurrent head and neck cancers previous treated with definitive radiation?
This is an area of active clinical trial development esp. as it relates to immunotherapy concurrent with SBRT. That being said, we certainly have phase I, II, and preliminary phase III data suggesting that SBRT in the setting of recurrent disease is safe and may offer extended LR control rates in a ...
How would you treat a second HPV related oropharyngeal squamous cell cancer in a patient previoulsy treated and cured of a HPV related SCC of the tonsil treated with chemoradiation?
At our institution, recurrent or second primary head and neck cancers are discussed at a multidisciplinary tumor board whenever possible. We review prior radiation records, physician's notes, and pre-treatment imaging to attempt to come to a consensus whether it is truly a second primary or perhaps ...
How would you manage recurrent laryngeal cancer after previous larynx xrt if surgical salvage not an option?
Re-RT for recurrent laryngeal cancer when surgery is not an option was first proposed by CC Wang (IJROBP 1993;26:783-5). He reported reasonable local control rates and stated, at the conclusion of “Radiation Therapy Results†in his paper, that “significant radiation sequelae… were not encoun...
How would you manage a small to medium sized but unresectable nodal recurrence within the original treatment volume for a head and neck squamous cell carcinoma?
There are a lot of points to consider before you can make this decision: what is the time interval from prior RT? what dose was received to this node from prior RT? what are the critical organs at risk if you were to treat this node? why is this node considered unresectable? how large is the nodal ...
What dose and fractionation do you use in the setting of head and neck reirradiation?
We have traditionally treated recurrent HNC with full standard fractionated RT concurrent with chemo. In recent years we have transitioned to SBRT, typically 40 Gy in 5 fractions. The use of SBRT is more convenient; current data suggest that both methods achieve similar tumor control rates and simil...